Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 47 Neoplasm Metastasis 9 Neoplasms 8 Prostatic Neoplasms 7 Brain Neoplasms 7 Endometrial Neoplasms 6 Glioblastoma 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Meningioma 3 Carcinoma, Renal Cell 3 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Oligodendroglioma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Liposarcoma 2 Hematologic Neoplasms 2 Glioma 2 Breast Neoplasms, Male 2 Breast Diseases 2 Breast Cancer Female 2 Venous Thromboembolism 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral Breast Neoplasms 1

Interventions

Cyclophosphamide 21 Cytarabine 15 blinatumomab 13 fludarabine 12 Azacitidine 10 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Methotrexate 7 Lenalidomide 7 Dexamethasone 7 Rituximab 6 Mercaptopurine 6 Daunorubicin 6 Vincristine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Etoposide 4 Busulfan 4 obinutuzumab 3 Radiotherapy 3 Neoadjuvant Therapy 3 Maintenance 3 Liquid Biopsy 3 Immunotherapy, Adoptive 3 Idarubicin 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Doxorubicin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasm, Residual × abemaciclib × Clear all

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡